The question is not "how do I gain weight" — it's "given I'm going to gain some fat, what determines whether it goes to my hips and breasts or my abdomen?"
Framed for MtF, but the biology is general. For lean-mass-focused bulking (protein targets, surplus optimization, creatine, training programming), see Upcycle Research.
The Question
Fat depot selection — whether new fat lands on your hips or your belly — is controlled primarily by hormones and genetics. In cis women, estradiol promotes adipogenesis in gluteofemoral (hip/thigh/buttock) depots and blunts it in abdominal depots. Testosterone does the opposite. This is why men and women store fat differently.
For MtF individuals, the practical implication is simple: get the hormone environment right, and new fat will preferentially go to the right places. Everything else on this page is either a supporting factor, a marginal tweak, or surgery.
If you do nothing else, get this right.
An estradiol-dominant, androgen-suppressed hormone profile is the single biggest determinant of where new fat goes. HRT alone produces gluteofemoral redistribution over 12 months without any cycling, dieting, or supplementation.
Estradiol biases new fat toward hips, thighs, breasts
C2
LPL activity is higher in gluteofemoral than abdominal fat under estradiol. Estradiol increases adipogenesis from gluteofemoral but not abdominal adipose-derived stem cells in postmenopausal women.
Elbers 1999 (MRI, n=20): +38% hip subq fat, +38% thigh subq fat at 12 months on feminizing HRT
Klaver 2017 meta-analysis (n=171): +3.0 kg fat, −2.4 kg lean at 12 months. Gynoid-biased.
Fighera cohort: +27% gynoid fat, +27% leg fat, android/gynoid ratio fell ~5% at 6 months — with near-zero total weight change.
The composition shift (more fat, less lean, biased toward hips/thighs) is consistent across essentially every prospective study of feminizing HRT. This happens without cycling.
Does weight cycling accelerate this beyond HRT alone?
C4
No peer-reviewed evidence. The argument is mechanistic (each gain cycle is a fresh biasing opportunity under estradiol) plus anecdotal (Dr. Will Powers, Mesityl's 2022 post). Mesityl herself acknowledges "we have no peer-reviewed evidence for this theory."
Adipocyte biology ceiling: Cell half-replacement ~8.3 years (Spalding 2008), but intracellular lipid turnover is faster (~1.6 years). Huge reshaping gains from a few cycles over one year are implausible. The effect, if it exists, is probably small and accumulates slowly.
Angus 2021 systematic review: body composition changes look similar across CPA / leuprolide / spironolactone at comparable T suppression. The depot biasing comes from estradiol + low T, not from which anti-androgen you use. But anti-androgen choice does affect whether you gain or lose total weight, which matters for how much raw material is available to be deposited.
Anti-androgen
Weight effect
Key risk
Depot relevance
Cyproterone (CPA)
Weight-gainer. Several kg/yr at high dose; less at modern 10–12.5 mg.
More raw material to deposit, but depot pattern is the same
DMPA
+2–3 kg/1yr, +5–6 kg/2–3yr
BMD black-box; delayed fertility return
Same — weight push, not depot change
Spironolactone
Neutral (initial ~1–2 kg loss from diuresis)
Hyperkalemia
None
Bicalutamide
Neutral
Hepatotoxicity (~1%)
None
GnRH agonists
Neutral
Cost; injection
None
Progesterone — does it help breasts/hips specifically?
C2 for the null result
Under-evidenced. The 2023 Dijkman RCT (n=82 post-orchiectomy trans women, micronized progesterone 200 mg/day vs placebo, 3 months) found no significant increase in breast volume. Earlier data showed higher satisfaction but not measurable volume difference. Appetite effect is weaker than CPA or DMPA. Low harm in short-term use but should not be described as evidence-based for depot-specific fat gain.
These don't determine whether you gain — they influence where the fat ends up, given that you're gaining.
Avoid alcohol
C2
Alcohol specifically pushes fat toward the abdomen and raises androgens in women — the exact opposite of the goal.
Tin Tin 2024 meta-analysis: per 10 g/d alcohol, ~4.3% higher total testosterone in premenopausal women
IJO 2026: >10% higher proportional visceral fat mass in women consuming >10 units/week
The androgen-raising effect is the specifically MtF-relevant part: adding an agent that nudges androgens back up and biases fat toward the abdomen is the opposite of what you want. Conservative recommendation: near-zero during a gain phase.
Tin Tin 2024 (alcohol & androgens meta-analysis + MR)
Sleep 7–9 hours
C1
Short sleep worsens the composition of weight gained — more fat goes to undesirable depots, less to lean tissue. Sleep deprivation raises cortisol and lowers testosterone, both of which bias fat storage toward visceral/abdominal.
Nedeltcheva 2010: 5.5h vs 8.5h sleep on matched intake — dramatically different fat/lean partitioning
More specifically for depot selection: cortisol drives visceral deposition (Epel 2000), which directly opposes the estradiol-driven gluteofemoral bias. Good sleep protects the depot-selection signal you're getting from HRT.
Manage chronic stress
C2
Same mechanism as sleep: sustained cortisol biases gained fat toward visceral depots. Epel 2000: high-WHR women (including lean ones) secreted significantly more cortisol under stress. For someone relying on estradiol to bias fat toward hips/thighs, chronic stress directly undermines that signal.
Fat source: prefer unsaturated over saturated
C2
When overeating, what you eat affects where it goes — not just how much.
Rosqvist 2014 LIPOGAIN: saturated-fat overfeeders gained 4x more visceral/liver fat. Polyunsaturated-fat overfeeders gained fat and lean roughly equally, with less visceral deposition.
Practical: prefer nuts, olive oil, avocado, fatty fish over palm oil, butter-heavy, high-saturated-fat sources when in a surplus. This is about depot selection, not total calories.
Oral pioglitazone: shifts fat from visceral to subcutaneous — and specifically to femoral
C1
Pioglitazone is an anti-diabetic PPAR-γ agonist producing ~2–4 kg weight gain over 6–12 months at 15–45 mg/day oral, with a depot-specific redistribution signal that is actually more targeted than "visceral down, subcutaneous up."
McLaughlin 2020 RCT (n=41 obese women, 30 mg/day, 16 weeks): new adipocyte formation increased +3.3% in the femoral (thigh) depot specifically (p=0.04) but NOT in abdominal subcutaneous fat (p=0.32). Visceral fat ratio decreased (p=0.002).
Miyazaki 2002: visceral fat decreased, subcutaneous fat increased vs. placebo in T2D.
This is the only non-hormonal agent with RCT-level evidence of selectively creating new fat cells in the femoral/gluteofemoral depot. The depot specificity aligns with the MtF goal better than "general subcutaneous" — the fat cells are being created preferentially in the hip/thigh area.
The one MtF case report: A 45-year-old trans woman on 13 years of estrogen, dissatisfied with "male body fat distribution," received rosiglitazone 2 mg/day (a related TZD) for 20 months. Waist: 100→82 cm. Thigh: 44→49 cm. Authors concluded TZDs "may have a place as therapy in achieving body shape change."
Community reports (grayoasis.com): One user reports observing "at least a dozen people" who used oral pio at 30 mg/day during intentional bulk: "their WHR improved, their thighs are more jiggly, their ass is fatter." Recommends max 6–12 months continuous use during active gain phase.
QueerDoc (conservative): Suggests 15 mg/day max for 3 months if at all, emphasizing "no research on pioglitazone in transgender patients" and risk/benefit unfavorable for most patients.
Safety trade-offs:
Fluid retention — dose-dependent; the first ~5 lbs of gain is often water
Heart failure signal — increased HF hospitalizations (PROactive trial)
Bone fracture risk — modest increase in distal fractures, particularly on HRT
Bladder cancer signal — up to 40% increased risk with 2+ years use / >28,000 mg cumulative (now considered smaller than initially feared)
May suppress breast glandular tissue — Mesityl argues PPARy has antiproliferative effect on mammary epithelium in vitro; could help breast fat but hurt breast glands
Honest comparison: The draft called pioglitazone "the single most effective tool for achieving female fat distribution." The McLaughlin 2020 RCT actually supports a stronger claim than previously thought — pio doesn't just shift visceral→subcutaneous, it specifically creates new fat cells in the femoral depot and not the abdominal depot. This aligns with the MtF goal well. But for a healthy person off-label: the heart failure, bone, and bladder signals make this a real trade-off. Conservative path: 15–30 mg/day during a deliberate gain phase only, max 3–6 months, with medical monitoring.
5. Topical Agents for Local Fat Growth
The dream · mostly unproven
Honest framing: The hope is "apply cream to hips/breasts, grow fat specifically there." The reality is that the entire category has no independent, blinded, imaging-endpoint RCT in humans at cosmetic concentrations. What exists is manufacturer brochure data, in-vitro assays, and forum anecdote.
Acetyl-Hexapeptide-38 (Adifyline)
C4
Lipotec/Lubrizol's synthetic peptide. Manufacturer brochure claims a few percent breast/cheek volume increase over 2 months at 2% w/w via PPAR-γ / PGC-1α upregulation.
Problems: All efficacy numbers trace to the manufacturer. PubMed returns zero independent efficacy RCTs. Peptides of ~700 Da penetrate skin poorly — estimated ~0.2% reaches the dermis, orders of magnitude below in-vitro effective concentrations.
Forum pattern: Subjective facial volume improvement reported more often than breast/thigh. Could be cheek fat responding to tiny changes, or could be moisturizer plumping. Cannot distinguish from anecdote.
DIY community pairs it with dermarolling to improve penetration. Reports are hit-or-miss. One user reported going from A/B to C-cup; others saw nothing.
The inverse: decreases PGC-1α, inhibits adipogenesis. Theoretical use: apply to undesired areas (abdomen, back) during a gain phase to suppress fat growth there. Very little literature; mentioned in Mesityl's post but essentially no data.
Volufiline (Sarsasapogenin)
C4
Sederma's cosmetic active. Brochure reports ~6.5% breast volume increase over 2 months via PPAR-γ. But the same brochure's own positive control (pioglitazone) produced ~500% adipocyte differentiation vs. volufiline's much smaller effect — the in-vitro data argue against the commercial product.
r/estrogel skeptical analysis: At ~0.2% dermal penetration of a 2% topical load, the delivered dose is far below the in-vitro EC50. "Expensive theatre rather than pharmacology." Some recommend buying raw sarsasapogenin directly for higher concentrations.
Topical Pioglitazone — does it work better locally?
C3
DIY practice: crushing oral pioglitazone tablets into a cream or gel base and applying to target areas. The hope is local PPAR-γ activation without systemic risks. The transdermal pharmacology is actually more nuanced than "it doesn't penetrate."
What the pharma literature says about skin penetration:
• Transdermal patch with enhancers (Duro-Tak adhesive + 5% propylene glycol): pioglitazone does cross skin and goes systemic. Rat study found ~2x higher bioavailability than oral. This means DIY creams with propylene glycol can absolutely go systemic.
• Nanoemulsion designed for local retention: pioglitazone stayed in skin (478 μg/g retention) and did not reach systemic circulation. But this was specifically engineered for dermatitis treatment, not fat growth, and no study has tested whether skin-retained pio activates PPAR-γ in the subcutaneous fat layer below.
• Microneedle + iontophoresis patches: significantly better delivery than oral in rats, clearly systemic.
The one detailed DIY report (r/DIYCosmeticProcedures, u/filthy_weeb_trash):
• Formulation: 0.08% pioglitazone + 5% adifyline solution in a hand sanitizer (propylene glycol-containing) base
• Applied to thighs and upper cheeks for ~2 months
• Results: "body is definitely fuller where I've been applying it, a distinct change in shape with more volume in those areas relative to other areas"
• But also: +14 lbs total weight gain, first 5 lbs in one week (water), appetite "through the roof", blood sugar crashes 2–4 hours after eating
• The blood sugar and appetite effects are classic systemic pioglitazone signs. The propylene glycol base is a known penetration enhancer. This person was likely getting systemic absorption, which means the "local" fat gain may just be systemic pioglitazone + dietary surplus doing what oral pio does — creating new fat cells preferentially in the femoral depot everywhere, not specifically where the cream was applied.
Bottom line on topical vs oral: A DIY cream with propylene glycol likely goes partially systemic, making it an uncontrolled-dose oral equivalent. A professionally engineered nanoemulsion can keep pio local in the skin, but no one has tested whether skin-level pio activates fat growth in the subq layer below. If you're going to take the systemic risk anyway, oral tablets give you dose control. The only reason to prefer topical is if a future formulation could truly deliver pio to subcutaneous fat locally without systemic exposure — that formulation doesn't exist yet.
Bottom line for topicals: If you want PPAR-γ agonism at useful levels, oral pioglitazone at 15–30 mg/day is the evidence-backed way to get it — it has RCT-level evidence of creating new fat cells specifically in the femoral depot (McLaughlin 2020). The cosmetic peptides (Adifyline, Volufiline) are trying to reach the same pathway through the skin at concentrations that probably can't do the job. Topical pioglitazone in a DIY cream likely goes partially systemic anyway, so you're getting an uncontrolled-dose version of what the pill does. Worth experimenting with the peptides if curious, but don't build your plan around them.
6. Exercise for Shape (Not for Mass)
Free · different framing than bodybuilding
The goal here is not maximizing lean mass gain (that's a different page). For selective fat distribution, exercise matters in two specific ways:
Lower-body training adds hip/thigh circumference directly
C2
Even a modest amount of glute/hamstring/thigh muscle adds visible hip circumference and improves waist-to-hip and shoulder-to-hip ratios. This is straightforwardly true regardless of fat partitioning — the muscle itself is the shape change.
Practical minimum: Hip thrusts or squats + Romanian/trap-bar deadlifts, 2x/week, 3 sets of 8–12 reps. Enough for significant improvement without excessive time commitment.
Upper-body caveat: Not contraindicated, but if the goal is a feminine silhouette, excessive trap/shoulder/deltoid development can work against it. A lower-body-biased volume tilt makes sense.
Exercise reduces waist circumference independent of weight
C2
You can gain or maintain total weight while the waist shrinks — exercise preferentially reduces android/visceral fat. This directly improves the ratios that matter for silhouette without requiring weight loss.
Does training a muscle area attract fat to that area?
C4
Speculative. The plausibility argument: training increases local blood flow and substrate uptake, which might nudge adjacent fat deposition. Two small positive studies exist (Brobakken 2023, Paoli 2021), but the spot-reduction meta-analysis is null overall. Don't rely on this — the muscle circumference gain alone justifies the training.
7. Surgical Fat Transfer
The direct solution · C1–C2
Fat transfer is the only method that directly moves fat from where you don't want it to where you do. For MtF patients, pelvic bone width is fixed in adults — the only way to change the visible hip silhouette is soft tissue. This is the largest single adjustable lever available.
Gluteal Fat Grafting (BBL)
C1 for safety data
Transfers 300–1200 mL per side. Retention ~50–70%. Stabilizes by ~6 months.
Safety has changed: Pre-2018 mortality ~1 in 3,000 (pulmonary fat embolism from intramuscular injection). After the 2018 Multi-Society Advisory mandating subcutaneous-only injection with ultrasound guidance: ~1 in 14,921 (2020 follow-up). 2025 meta-analysis of 22,151 subcutaneous-technique cases: PFE rate 0.04%.
The question in 2026: Not "is BBL safe?" but "is my surgeon adherent to post-2018 subcutaneous-only guidelines with ultrasound guidance in an accredited facility?"
Cost: $7,000–17,000 US board-certified. Budget quotes of $3,000–6,500 are associated with the high-mortality medical-tourism cluster.
Recovery: No sitting 2–3 weeks; BBL pillow weeks 3–8; normal sitting ~6–8 weeks.
150–300 mL per breast per session. ~0.5–1 cup gain per session, 50–60% retention. Achieving >1.5 cups usually requires 2–3 sessions spaced ~6 months.
BRAVA pre-expansion: Wearing negative-pressure device ~10h/day for 4 weeks pre-op increases retention to ~66%. Demanding but real benefit.
vs. Implants: Fat = lower complication rate, no capsular contracture, more natural. Implants preferred for >1 cup in a single procedure or if insufficient donor fat.
Oncologic safety: No excess recurrence vs. controls (2018 meta-analysis, 2022 BMC Cancer review).
Lateral Hip / Hip-Dip / 360° Contouring
C2
100–400 mL per side, often combined with waist/flank liposuction. Targets the trochanteric depression ("hip dip"). Most directly relevant to MtF silhouette.
Safety profile better than gluteal — no large deep venous structures to embolize through. Retention ~50–70%. Often done in the same session as BBL.
You need donor fat: the upcycle prerequisite
C2
BMI <18.5 is generally a contraindication. Surgeons routinely advise thin patients to gain weight for 3–6 months pre-operatively. This is the clinical reason the "upcycle" concept connects to fat transfer — the patient needs adipose to harvest.
Hard no: non-autologous gluteal fillers. HA, PLLA, and especially illegal industrial silicone are explicitly FDA-warned. Documented fatalities, granulomatous reactions, migration. Not a shortcut.
8. What Doesn't Help With Depot Selection
Things that affect weight but not where
These are sometimes discussed as upcycle tools, but they affect how much you gain, not where it goes. They belong in a general weight-gain or lean-bulking context, not here.
Intervention
What it actually does
Depot relevance
Creatine
~1 kg lean + 1–2 kg water. Best bulking supplement.
None. Adds lean mass and water, not fat, and does not influence where fat goes.
Protein supplementation
Helps hit daily protein target
None for depot selection
Surplus size
Determines how much you gain
Marginal: excessive surplus may tilt toward visceral (less well-controlled). Modest surplus is still better.
None for depot selection. Full psychiatric/metabolic side-effect profiles. Not defensible for cosmetic bulking.
Peptides & Growth Hormone
C4 for depot relevance
These affect how much you gain (marginally), not where.
MK-677: +2.7 kg in elderly, mostly water. No depot-selection effect. CHF signal in frail elderly.
Anamorelin: ~0.65–0.99 kg LBM in cachexia. No handgrip benefit, no depot-selection data.
CJC-1295 / Ipamorelin / Sermorelin: Zero body-composition RCT evidence, let alone depot-selection data.
Tesamorelin: Approved to reduce visceral fat. Wrong direction for gaining, but actually the right depot-shifting direction if you could combine it with gain. No data for this use case.
Somatropin: ~2 kg lean mass shift, mostly water, no functional gain. No depot-biasing signal.
None of these are recommended for selective fat gain.
9. Danger Bin
Do not use
Method
Why
Anabolic steroids / SARMs
Actively oppose feminization. Promote android/visceral fat distribution, suppress gluteofemoral adipogenesis. Undo the HRT signal. SARMs additionally: no FDA approval, ~41% label mismatch (2017 JAMA), hepatotoxicity cases.
Insulin abuse
Hypoglycemic coma and death. Multiple bodybuilding fatalities.
Apetamin / adulterated cyproheptadine
FDA warning: liver injury, cardiac events, deaths. Products adulterated with undeclared steroids.
GLP-1 / GIP agonists while trying to gain: Semaglutide, tirzepatide, etc. suppress appetite by design. If you're currently on one and want to upcycle, the drug directly fights the goal. Discontinuation causes unpredictable regain — which you might think is convenient, but the regain pattern hasn't been studied for depot selection.
Hypothetical local PPAR-γ. No independent human imaging RCT.
C4
Experiment if curious; don't rely on
Peptides / GH
No depot-selection evidence. Affect mass (marginally), not location.
C4
Not relevant to this question
Anabolic steroids / SARMs
Promote android pattern; undo HRT signal
C2
Actively harmful
The honest picture: There are really only a few things that influence where fat goes: hormones (the big one), avoiding things that push visceral (alcohol, sleep deprivation, chronic stress, saturated fat excess), pioglitazone (real but with safety trade-offs), and surgery (the direct route). The topical creams are a reasonable experiment but sit on manufacturer data and forum reports. Everything else in the weight-gain world affects how much you gain, which is a different question.